Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

  • George Mulligan
  • , David I. Lichter
  • , Alessandra Di Bacco
  • , Stephen J. Blakemore
  • , Allison Berger
  • , Erik Koenig
  • , Hugues Bernard
  • , William Trepicchio
  • , Bin Li
  • , Rachel Neuwirth
  • , Nibedita Chattopadhyay
  • , Joseph B. Bolen
  • , Andrew J. Dorner
  • , Helgi Van De Velde
  • , Deborah Ricci
  • , Sundar Jagannath
  • , James R. Berenson
  • , Paul G. Richardson
  • , Edward A. Stadtmauer
  • , Robert Z. Orlowski
    • Sagar Lonial, Kenneth C. Anderson, Pieter Sonneveld, Jeśus F.San Miguel, Dixie Lee Esseltine, Matthew Schu

Research output: Contribution to journal › Article › peer-review

110 Scopus citations

Fingerprint

Dive into the research topics of 'Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy'. Together they form a unique fingerprint.

Keyphrases

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science